Scribe Therapeutics, Inc. (SCTX)

15.7 USD+2.15%
Gurus hold1popularity #1267 of 1982
Net buying (quarter)+$0.000 buying · 0 selling
Market Cap$297.3M
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.—

Scribe Therapeutics, Inc. (SCTX) is not among the 30 most-held stocks of the tracked superinvestor set. Price 15.70 USD; market cap $297.3M.

Guru Ownership

Popularity rank#1,267 of 1,982 securities
gurus hold it1
Net activity this quarter+$0.00

Guru count: the consensus-panel funds (wide books such as Citadel or Renaissance excluded) holding the stock at quarter end; the header and the history table use the same definition.

What changed this quarter
$0.00 · 0 new buys · 0 added $0.00 · 0 reduced · 0 sold out0 net buyers · 0 net sellers1 funds held it before the IPO (not counted as buying) · $14.5M
Top 5 by conviction
Top 5 by value

Price & valuation

Prev Close15.37
Open15.39
Day Range14.7 – 16.01
52 Week Range—
Volume—
Avg Volume (3M)—
Market Cap$297.3MSEC 10-Q, 11/06/2026
BetaVolatility vs the market. Above 1: swings harder than the index.—
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.—
EPS (TTM)Annual net profit per share.—
Dividend YieldAnnual dividend over share price.—

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Frequently Asked Questions

Which superinvestors own SCTX?

Scribe Therapeutics, Inc. (SCTX) is not among the 30 most-held stocks of the tracked superinvestor set.

Is institutional sentiment on SCTX bullish or bearish?

SCTX is not among the 30 most-held stocks of the superinvestor set, so net buyer/seller counts are not computed for it.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.